ArticleAnnals of the rheumatic diseases2014
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA).
Article in Annals of the rheumatic diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 380 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
380 citing papers in PubMed, 7 syntheses or guidelines pooled it, 848 citations in OpenAlex.
- Meta-Analysis of the Incidence and Influencing Factors of Malignant Tumors in Patients with Rheumatoid Arthritis.Journal of epidemiology and global health · 2026Pooled it
- Prevalence and risk of chronic obstructive pulmonary disease in rheumatoid arthritis: Systematic review and meta-analysis.Medicine · 2026Pooled it
- Maternal and fetal outcomes in pregnant women with rheumatoid arthritis: a systematic review and meta-analysis.Clinical rheumatology · 2023Pooled it
- Rheumatoid arthritis and risk of site-specific cancers: Mendelian randomization study in European and East Asian populations.Arthritis research & therapy · 2022Pooled it
- Examining the Relationship Between Rheumatoid Arthritis, Multimorbidity, and Adverse Health-Related Outcomes: A Systematic Review.Arthritis care & research · 2022Pooled it
- 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis.Annals of the rheumatic diseases · 2021Guideline
- Diagnostic value of anti-cyclic citrullinated peptide antibody combined with rheumatoid factor in rheumatoid arthritis in Asia: a meta-analysis.The Journal of international medical research · 2021Pooled it
- The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial.Arthritis research & therapy · 2025Trial
- Digital Psychological Intervention for Inflammatory Rheumatic Diseases: A Pilot Randomized Clinical Trial.JAMA network open · 2025Trial
- Trial
- Efficacy of Olokizumab against Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of the Study.Doklady. Biochemistry and biophysics · 2024Trial
- Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants.Clinical pharmacology in drug development · 2022Trial
- Salivary citrullinated proteins in rheumatoid arthritis and associated periodontal disease.Scientific reports · 2021Trial
- Diagnostic, prognostic and therapeutic biomarkers in rheumatoid arthritis.Nature reviews. Rheumatology · 2026Review
- Psychological Aspects of Rheumatic Diseases: Psychorheumatology in Clinical Practice.Rheumatology and therapy · 2026Review
- Comorbidity Profiles at Diagnosis in Rheumatoid Arthritis Versus Psoriatic Arthritis: A Nationwide Polish Claims-Based Study.Journal of clinical medicine · 2026Article
- Between Guidelines and Daily Practice: The Persistent Use of Parenteral Depot Corticosteroids in Germany.Clinical and translational allergy · 2026Article
- A comprehensive review on thermo-responsive targeted and functional therapy for management of rheumatoid arthritis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Cognitive impairment risk in patients with rheumatoid arthritis: a population-based cohort study.RMD open · 2026Article
- Prednisone prescribing for rheumatoid arthritis management in primary care: Mixed-methods study of trends and patient perspectives.Canadian family physician Medecin de famille canadien · 2026Article
320 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
24 authors at 20 institutions in 19 countries.
Funding
Abstract
backgroundPATIENTS with rheumatoid arthritis (RA) are at increased risk of developing comorbid conditions.
objectivesTo evaluate the prevalence of comorbidities and compare their management in RA patients from different countries worldwide.
methodsSTUDY
designinternational, cross-sectional. PATIENTS: consecutive RA patients. DATA COLLECTED: demographics, disease characteristics (activity, severity, treatment), comorbidities (cardiovascular, infections, cancer, gastrointestinal, pulmonary, osteoporosis and psychiatric disorders).
resultsOf 4586 patients recruited in 17 participating countries, 3920 were analysed (age, 56±13 years; disease duration, 10±9 years (mean±SD); female gender, 82%; DAS28 (Disease Activity Score using 28 joints)-erythrocyte sedimentation rate, 3.7±1.6 (mean±SD); Health Assessment Questionnaire, 1.0±0.7 (mean±SD); past or current methotrexate use, 89%; past or current use of biological agents, 39%. The most frequently associated diseases (past or current) were: depression, 15%; asthma, 6.6%; cardiovascular events (myocardial infarction, stroke), 6%; solid malignancies (excluding basal cell carcinoma), 4.5%; chronic obstructive pulmonary disease, 3.5%. High intercountry variability was observed for both the prevalence of comorbidities and the proportion of subjects complying with recommendations for preventing and managing comorbidities. The systematic evaluation of comorbidities in this study detected abnormalities in vital signs, such as elevated blood pressure in 11.2%, and identified conditions that manifest as laboratory test abnormalities, such as hyperglycaemia in 3.3% and hyperlipidaemia in 8.3%.
conclusionsAmong RA patients, there is a high prevalence of comorbidities and their risk factors. In this multinational sample, variability among countries was wide, not only in prevalence but also in compliance with recommendations for preventing and managing these comorbidities. Systematic measurement of vital signs and laboratory testing detects otherwise unrecognised comorbid conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.